This work will test the hypothesis FUS-induced blood-brain barrier disruption can be used to deliver irinotecan to the brain and to a brain tumor model without toxicity. We will use the 230 kHz ExAblate Neuro clinical transcranial MRI-guided FUS system for these tests. First, in healthy rats we will deliver free and liposomal irinotecan across the BBB and use histology to confirm that such delivery is not neurotoxic. Next, we will evaluate this chemotherapy agent in a rat glioma model. At 3-4 weeks after sonication, we will examine the brains in histology to assess tumor volume, side effects, and infiltration in comparison to animals that did not receive focused ultrasound-induced BBB disruption.